(2S)-5-methylpyrrolidine-2-carboxylic acid | 681128-94-9

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (2S)-5-methylpyrrolidine-2-carboxylic acid
• 英文别名: cis- and trans-5-methyl-(S)-proline；5-methyl-L-proline
• CAS: 681128-94-9
• 化学式: C₆H₁₁NO₂
• 分子量: 129.159
• InChiKey: YNSYWEFVEIFJPZ-AKGZTFGVSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.9
• 重原子数：
  9
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.83
• 拓扑面积：
  49.3
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (2S)-5-methylpyrrolidine-2-carboxylic acid 在 sodium hydroxide 、 benzotriazol-1-yloxyl-tris-(pyrrolidino)-phosphonium hexafluorophosphate 、 N,N-二异丙基乙胺 作用下， 以 1,4-二氧六环 为溶剂， 生成 1,1-Dimethylethyl (2S)-2-[(methoxymethylamino)carbonyl]-5-methyl-1-pyrrolidinecarboxylate
  参考文献：
  名称：

  Discovery and initial structure–Activity relationships of trisubstituted ureas as thrombin receptor (PAR-1) antagonists

  摘要：

  Thrombin is the most potent agonist of platelet activation, and its effects are predominantly mediated by platelet thrombin receptors. Therefore, antagonists of the thrombin receptor have potential utility for the treatment of thrombotic disorders. Screening of combinatorial libraries revealed 2 to be a potent antagonist of the thrombin receptor. Modifications of this structure produced 11k, which inhibits thrombin receptor stimulated secretion and aggregation of platelets. (C) 2001 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(01)00538-8
• 作为产物：
  描述：

  methyl (2S)-1-(2,2-dimethylpropanoyl)-5-methylpyrrolidine-2-carboxylate 生成 (2S)-5-methylpyrrolidine-2-carboxylic acid
  参考文献：
  名称：

  MOSS, WILLIAM O.;BRADBURY, ROBERT H.;HALES, NEIL J.;GALLAGHER, TIMOTHY, TETRAHEDRON LETT., 31,(1990) N9, C. 5653-5656

  摘要：

  DOI：

文献信息

• [EN] MULTICOMPONENT CRYSTALLINE SYSTEM OF EZETIMIBE AND PROLINE<br/>[FR] SYSTÈME CRISTALLIN À PLUSIEURS COMPOSANTS CONSTITUÉ D'ÉZÉTIMIBE ET DE PROLINE
  申请人：BASF SE

  公开号：WO2013014604A1

  公开（公告）日：2013-01-31

  Provided is a crystalline composition comprising a mixture of a compound of formula 1 (Ezetimibe) and proline or proline derivatives, or a hydrate/solvate thereof, as well as a process for obtaining the same. And a process for the purification of Ezetimibe is also disclosed.

  提供了一种结晶组合物，该组合物包括公式1化合物（依折麦布）和脯氨酸或脯氨酸衍生物的混合物，或其水合物/溶剂化物，以及获得同一组合物的过程。还公开了一种用于纯化依折麦布的过程。
• [EN] QUINAZOLINE DERIVATIVES<br/>[FR] DERIVES DE QUINAZOLINE
  申请人：ASTRAZENECA AB

  公开号：WO2005026156A1

  公开（公告）日：2005-03-24

  The invention concerns quinazoline derivatives of Formula (I) wherein each of R1, R3, R20, X1, X2, Z, W, (a) and (q) have any of the meanings defined in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use as an antiproliferative agent in the prevention or treatment of turnours which are sensitive to inhibition of erbB receptor tyrosine kinases, particularly EGFR tyrosine kinase.

  这项发明涉及式(I)的喹唑啉衍生物，其中R1、R3、R20、X1、X2、Z、W、(a)和(q)中的每一个具有描述中定义的任何含义；它们的制备方法，含有它们的药物组合物以及它们在制造用作抗增殖剂的药物时的用途，用于预防或治疗对erbB受体酪氨酸激酶抑制敏感的肿瘤，特别是EGFR酪氨酸激酶。
• [EN] SUBSTITUTED PYRROLIZINE COMPOUNDS AND USES THEREOF<br/>[FR] COMPOSÉS DE PYRROLIZINE SUBSTITUÉS ET LEURS UTILISATIONS
  申请人：GILEAD SCIENCES INC

  公开号：WO2018039531A1

  公开（公告）日：2018-03-01

  This application relates to substituted fused pyrrole compounds of formula I, and pharmaceutical compositions comprising them which inhibit HBV replication, and methods of making and using them. Formula (I)

  这种应用涉及到式I的取代融合吡咯化合物，以及包含它们的抑制HBV复制的药物组合物，以及制备和使用它们的方法。公式（I）
• Inhibitors of hepatitis C virus NS3 protease
  申请人：——

  公开号：US20020065248A1

  公开（公告）日：2002-05-30

  The present invention relates to compounds of Formula (I): 1 wherein A 1 is methylene, ethylene or propylene group and A 2 is N or CR 5 , or stereoisomeric forms, stereoisomeric mixtures, or pharmaceutically acceptable salt forms thereof, which are useful as inhibitors of HCV NS3 protease, and to pharmaceutical compositions and diagnostic kits comprising the same, and methods of using the same for treating viral infection or as an assay standard or reagent.

  本发明涉及化合物的结构公式（I）：其中A1为亚甲基、乙烯基或丙烯基，A2为N或CR5，或其立体异构体形式、立体异构体混合物或药用盐形式，用作HCV NS3蛋白酶的抑制剂，以及包含相同化合物的药物组合物和诊断试剂盒，以及用于治疗病毒感染或作为测定标准或试剂的方法。
• Peptide-Based Beta Turn Mimetics
  申请人：Zhang Kaidong

  公开号：US20100256333A1

  公开（公告）日：2010-10-07

  Beta-mimetic compositions and methods of making and using such compositions in preparing bioactive peptides, such as antimicrobial peptides, are disclosed. In particular, spirocyclic proline hybrids are provided that may be used to alter the cis/trans isomerization of proline in a peptide, and which may replace a residue, for example, the i+2 residue, of a beta-turn in a peptide of known sequence, thereby retaining or modifying the structure of the peptide.

  本发明揭示了一种β-模拟合成物及其制备和使用方法，用于制备生物活性肽，例如抗微生物肽。具体地，提供了螺环脯氨酸杂交体，可以用来改变肽中脯氨酸的顺反异构化，并且可以替换已知序列肽中的残基，例如i+2残基，从而保留或修改肽的结构。